The treatment, the first of its kind, was approved by the Food and Drug Administration on Thursday. “Our baby was born deaf, ...

Groundbreaking AAV-based gene therapy offers potential treatment for patients with OTOF gene-associated severe-to-profound and profound hearing lossWhite Oak, Md., April 24, 2026 (GLOBE NEWSWIRE) -- ...

The FDA has granted an accelerated approval for Otarmeni (lunsotogene parvec-cwha), the first gene therapy to treat patients ...

The Food and Drug Administration on Thursday approved Regeneron’s Otarmeni, the first gene therapy for genetic hearing loss ...

The U.S. Food and Drug Administration on Thursday approved the first gene therapy for inherited hearing loss, a one-time ...

The U.S. Food and Drug Administration (FDA) has approved the first-ever gene therapy for inherited deafness.

Formerly known as DB-OTO, lunsotogene parvec is an adeno-associated virus (AAV) vector–based gene therapy administered via a ...

Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s ...

Approved Thursday via the FDA's Commissioner’s National Priority Voucher program, Otarmeni is the first gene therapy for ...

Travis Smith was a very serious baby. Born completely unable to hear, his mother Sierra struggled to see his personality ...

All congenital deafness patients who completed the effective 2.5-year follow-up in a nationwide multicenter clinical study ...

Researchers say a gene therapy allowed deaf children and adults as old as 32 to hear for the first time. The benefits have ...